JNJ vs DXCM
By Alex · Tickerpine
Johnson & Johnson vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | DXCM |
|---|---|---|
| Price | $254.66 | $70.14 |
| Market cap | $613.02B | $27.07B |
| P/E ratio | 29.5 | 30.1 |
| ROE | 26.42% | 35.62% |
| Profit margin | 21.83% | 19.31% |
| Revenue growth | 9.90% | 15.00% |
| Dividend yield | 2.10% | — |
| Beta | 0.26 | 1.44 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs DXCM in plain English
- JNJ is the bigger company — about 22.6× the market cap of DXCM.
- JNJ is cheaper on earnings (P/E 29.5 vs 30.1).
- DXCM earns a higher return on equity (36% vs 26%).
- DXCM is growing revenue faster (15% vs 10%).
- JNJ pays a dividend (2.10%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.